Abstract. Type 2 diabetes mellitus is associated with a high risk of cardiovascular complications, including left ventricular remodeling and diastolic dysfunction. These pathological changes contribute to the development of diabetic cardiomyopathy and heart failure. This article evaluates the effects of Sodium-Glucose Cotransporter-2 (SGLT2) inhibitor therapy on left ventricular remodeling parameters and diastolic function in patients with type 2 diabetes mellitus. Particular attention is given to the mechanisms of cardioprotection, echocardiographic indicators of cardiac structure and function, and the potential role of SGLT2 inhibitors in preventing adverse cardiovascular outcomes. Recent studies have demonstrated that SGLT2 inhibitors contribute to reverse cardiac remodeling, reduce left ventricular mass, improve ventricular geometry, and enhance diastolic performance. In addition, these agents significantly decrease the risk of hospitalization for heart failure and improve overall cardiovascular prognosis. The findings indicate that SGLT2 inhibitor therapy provides substantial benefits beyond glycemic control and represents an important therapeutic strategy for improving cardiac structure and function in patients with type 2 diabetes mellitus.